LinkedIn Icon
March 19-21, 2019 | Boston, MA

 

 

Day One
March 20, 2019

Day Two
March 21, 2019

08.30
Chair’s Opening Remarks

08.40
Navigating the complex ICI-IO landscape – Recent updates and Future Challenges

  • Mark Yore Manager of Corporate Development , Jounce Therapeutics

Synopsis

  • As the number of CPI-IO trials continue to grow at unprecedented rates, understanding the complex nature of this landscape is critical for clinical and commercial success.
  • During the presentation I will discuss the landscape as it stands today, how it’s evolving, and key challenges that face ICI-containing IO-combinations in the future

09.10
Establishing a New Set of Biological Goals for Checkpoint Inhibitors and IO Combinations

  • Paul Rennert President and Chief Scientific Officer, Aleta Biotherapeutics

Synopsis

  • Look at the current standards that are in place for ICIs and IO combinations
  • Set new goals that scientists must strive to achieve in order to set a new standard of care

09.40
Model Aided Drug Invention Case Study: GITR-mediated T cell dynamics in Mouse Tumor Micro Environment

  • John Burke President, Chief Executive Officer & Co-founder, Applied Biomath

Synopsis

  • Model Aided Drug Invention (MADI) is a mechanistic mathematical modeling approach used tohelp reduce late stage attrition rates, help accelerate the development of premier (or best-in-class) therapeutics and identify potential R&D hurdles.
  • In this collaboration, a MADI approach was used to develop and analyze a systems pharmacology model of an anti-GITR (Glucocorticoid-Induced TNFRRelated protein)agonist antibody to predict Treg and Teff dynamics in the tumor microenvironment in two syngeneic mouse models following administration of anti-GITR agonist antibody.
  • The model adequately described the time profiles of intratumoral Treg and Teff, captured Teff immune checkpoint, Treg depletion by ADCP, and Teff proliferation and differentiation into cytotoxic T lymphocytes (CTLs). The model also provided a quantitative understanding of the trade-off between maximizing Treg depletion vs. Teff agonism

10.10
Speed Networking & Morning Refreshments

Broadening Understanding of the Biological Effects of Checkpoint Inhibitors

11.30
Supercharging the Tumor Microenvironment: Lessons from NKTR-214 and Opdivo

Synopsis

  • The idea of combining the immune modulating properties of checkpoint inhibitors and the immune stimulating function of engineered cytokines is conceptually powerful
  • Cytokine engineering can alternative cytokines to be more powerful medicines, while controlling adverse events
  • The combination of NKTR-214 with opdivo has demonstrated powerful anti tumor effects and profoundly alters the tumor microenvironment, increasing effector T-cell counts, increasing PD-1 expression on tumor T-cells, and converting PD-L1 negative tumors to positive, while maintaining a more tolerable AE profile than traditional cytokine therapies

12.00
A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug Discovery and Development

  • Mark Paris Director - Translational Applications, Mitra Biotech

Synopsis

  • Mitra Biotech has developed and clinically validated a fully human ex-vivo tumor platform technology (CANscript™)
  • CANscript ™ uses patient material (tumor, autologous ligands and PBMCs) to explore the mechanism of action and predict efficacy for clinically-directed compounds in a modality agnostic way using phenotypic readouts
  • This talk will explore how we use CANscript to measure the effect of checkpoint inhibitor monotherapy or combination to deepen our understanding of response and resistance

12.30
Lessons Learned from a Clinical Trial Targeting ICOS

  • Beth Trehu Chief Medical Officer , Jounce Therapeutics

Synopsis

  • JTX-2011, an ICOS agonist, was evaluated as monotherapy and in combination with nivolumab in the ICONIC trial
  • Responses and tumor reductions observed with monotherapy and combination were associated with a mechanism related pharmacodynamic biomarker
  • Reverse translational analyses enabled by biomarkers have redirected JTX-2011 clinical development strategy

13.00
Lunch

Enhancing Therapy Efficacy at the Preclinical Level

14.00 RNAi-mediated Inhibition of β-catenin IncreasesnResponses to Multiple Immunotherapy Regimens Across a Spectrum of Preclinical Tumor Models

  • A systemically-administered RNAi drug product targeting β-catenin increases APCs and cytotoxic T-cells in the TME, and promotes synergistic efficacy in combination with immunotherapy in multiple preclinical models
  • Identification of a novel mechanism by which Wnt/β- catenin signaling promotes resistance to immunotherapy
  • Strategies to rationally design RNAi-containing drug combinations to increase the response rates to checkpoint blockade and IDO inhibition

Shanthi Ganesh, Associate Director – Oncology, Dicerna

14.30 Delineating Myeloid Cell Subsets and Their Role in Response to Cancer Immunotherapy

  • Myeloid cell subsets associated with immune suppression and immune activation in cancer
  • Combination therapies reveal new insights into the proand anti-tumor contribution of myeloid cells in cancer
  • Emerging novel strategies for targeting myeloid cells to enhance cancer immunotherapy

Amy-Jo Casbon, Scientist – Oncology Research, Amgen

15.00 Bispecific and Biparatopic Human Heavy Chain Antibodies in Immune Oncology

  • Discuss different formats of T cell engaging bispecific antibodies
  • Explore biparatopic heavy chain antibodies against CD38

Wim Van Schooten, Chief Scientific Officer, TeneoBio

Overcoming Resistance & Personalizing Combination Therapies

14.00 Targeting the PI3K Pathway to Overcome Immune Resistance

  • Discuss how tumor intrinsic signaling pathways modulate T cell-mediated antitumor immune responses.
  • Identification of the mechanism by which oncogenic activation of the PI3K pathway promotes immune resistance
  • Development of therapeutic strategies to improve the efficacy of cancer immunotherapy by combining with
    PI3K inhibition

Weiyi Peng, Assistant Professor, MD Anderson Cancer Centre

14.30 Challenges and Solutions: Enabling Multidimensional Tumor Immunogenomics for advancing biomarker discovery

  • Insight into the complex and dynamic interactions
    between the tumor and immune cells of the
    microenvironment is essential for cancer
    immunotherapy biomarker discovery
  • Purpose built for precision oncology, the ImmunoID
    NeXT Platform investigates key areas of tumor biology;
    from elucidating mechanisms of tumor escape and
    detecting neoantigens, to characterizing the immune
    repertoire and identifying novel biomarker signatures
  • We’ll discuss the current challenges facing investigators
    in immuno-oncology translational research including
    maximizing data generation from a single sample and
    the analysis of complex data

Christelle Johnson, PhD, Senior Field Applications
Scientist, Personalis

15.00 Local Tumor Control with Distance Tumor Impact : First in Class NBTXR3

  • From Concept to clinical POC
  • Immuno oncology impact and combination evaluation
  • Leveraging product potential through MD Anderson Cancer Center Alliance

Patrick Tricoli, Chief Executive Officer, Nanobiotix

15.30
Afternoon Refreshments

Stages 1 – 3: Improving Cancer Antigen Presentation, Driving Stronger Priming and Immune Activation

16.00
Discover how Utilisation of the STING pathway has Bolstered the Effectiveness of PD-L1

Synopsis

  • Hear an update on the novel STING pathway system uses interferon expression to activate the innate response
  • Understand how ICI’s work with the innate immune system to improve effectiveness of preventing metastasis

16.30
T Cell Dysfunction and Combination Immunotherapy

Synopsis

  • Single-cell analysis of tumor-infiltrating lymphocytes to probe the mechanisms for combination immunotherapy
  • PD1/GITR combination immunotherapy led to a synergistic increase in tumor antigen–specific memory precursor effector T cells dependent on availability of the CD226 costimulatory pathway

17.00
Chair’s Closing Remarks